A new reversed-phase high-pressure liquid chromatography assay procedure for dihydropteroate synthetase (DHPS) that involves the elution of the enzyme incubation solution with a series of three solvents of decreasing polarity (ammonium phosphate buffer, 10% methanol, and 50% methanol) was designed. By this procedure DHPS was detected in Escherichia coli and Pneumocystis carinii with specific activities of 450 and 14 U/mg, respectively. A comparison of the effects of five sulfa drugs on P. carinii DHPS activity revealed that dapsone is the most potent of these drugs.
Pneumocystis carinii is the major life-threatening opportunistic agent in patients with acquired immunodeficiency syndrome (AIDS) and affects other immunocompromised patients. Approximately 60% of all patients with AIDS suffer from P. carinii pneumonia, and up to 40% of the episodes prove fatal (10) .
Patients with P. carinii pneumonia are frequently treated with antifolates (inhibitors of tetrahydrofolate biosynthesis) such as bactrim (a combination of trimethoprim and sulfamethoxazole) (6, 7) , dapsone (6, 13) , and trimetrexate (1) . The ability of P. carinii to synthesize tetrahydrofolate de novo has been reported recently (9) .
Two enzymes involved in the biosynthesis of tetrahydrofolate that are important as targets of antifolates are dihydropteroate synthetase (DHPS) and dihydrofolate reductase. DHPS catalyzes the formation of dihydropteroate (DHP) from p-aminobenzoic acid (pAB) and 6-hydroxymethyldihydropterin pyrophosphate (MDHP-PP). Dihydrofolate reductase catalyzes the formation of tetrahydrofolate from dihydrofolate. Sulfones and sulfonamides act as competitive inhibitors of DHPS substrates, while drugs such as trimethoprim and pyrimethamine act as inhibitors of dihydrofolate reductase substrates. In this study we measured the inhibitory actions of several sulfonamides and sulfones on the parasite associated with DHPS using a new high-pressure liquid chromatography (HPLC) enzyme assay.
MATERIALS AND METHODS
Growth and isolation of organisms. Male Sprague-Dawley rats (weight, 150 to 200 g) were fed ad libitum and administered tetracycline in their drinking water (1 g/liter). Subcutaneous injections of cortisone acetate (25 mg) were given twice a week. After 4 to 6 weeks of injections, those rats which showed signs of rapid breathing, blood in their noses, weight loss, and hair loss were used in the experiments.
P. carinii was isolated by a modification of the method of Gradus and Ivey (4). Each rat was sacrificed by cervical dislocation. Their lungs were then quickly removed and kept at 4°C. Touch preparations were made from the lungs and stained with toluidine blue (3) bacteria were evident. Subsequent inoculation of the lung homogenate onto Luria broth agar plates confirmed the absence of contaminants. The lungs were homogenized by repeated passage through a 60-gauge wire screen. The resulting suspension was centrifuged at 2,000 x g for 10 min. The supernatant was discarded, and the pellet was suspended in phosphate-buffered saline. The suspension was carefully layered onto a preformed (40 min) 20% Percoll gradient. After 40 min of centrifugation at 20,000 x g, the fluffy layer just above the lung tissue layer was removed. This layer was diluted with phosphate-buffered saline and spun at 2,000 x g for 10 min. The supernatant was discarded, and impression slides were made from the pellet. Usually, a pure preparation could be obtained with relatively few mammalian cells (<1%). When excessive mammalian cells or bacteria were observed, the organisms were discarded.
Extraction of proteins from P. carinui. The P. carinii organisms were suspended in 1 ml of phosphate-buffered saline buffer and were sonicated. The suspension was microfuged at 8,000 x g for 10 min (Brinkmann Instrument Inc., Westbury, N.Y.). The supernatant was concentrated with a Centricon-30 concentrator (Amicon Corp., Danvers, Mass.). Protein concentrations were determined by the method of Bradford (2) .
Synthesis of phosphorylated pteins. Phosphorylated pterins were prepared by a modification of the methods described by Shiota et al. (16) , in which 50 mg of 2-amino-4-hydroxy-6-hydroxymethylpteridine and 5 g of pyrophosphoric acid were added to a 25-ml, glass-stoppered Erlenmeyer flask. The mixture was protected from light and stirred in a water bath at 60°C for 12 h. The contents were transferred to a larger flask after the addition of 30 ml of cold distilled water. A volume of 5 ml of 15% Norit A (acid washed) was added to the mixture and stirred for a few minutes and then filtered through a 0.45-,um-pore-size filter (Millipore Corp., Bedford, Mass.). The filter was washed with 250 ml of distilled water, and thereafter, the adsorbed pteridines were eluted by adding 50 ml of an eluting reagent (equal volumes of 3 N NH40H and absolute ethanol). The mixture was stirred for a few additional minutes. This elution step was repeated four times, and the filtrates were pooled and evaporated to approximately 5 ml. The concentrated filtrate was applied to a Dowex-50 column, and the column was eluted with water until the effluent indicated no detectable fluorescence (monitored at 350 nm).
The eluate from the Dowex-50 column then was applied to a DEAE-cellulose column on-line in a fast-performance liquid chromatography unit (Pharmacia, Inc., Piscataway, N.J.). Gradients of 1 liter of 50 mM LiCl in 50 mM Tris hydrochloride (pH 7.2) and 150 mM LiCl in 50 mM Tris hydrochloride (pH 7.2) were used to develop the column. The column was allowed to flow at a rate of 8 ml/min. The elution of phosphorylated pteridines was monitored at 254 nm. Fractions from each peak were pooled and assayed for PPi (5) . Fractions containing PP1 were lyophilized and washed several times with absolute ethanol. The resulting pellet was dried with a concentrator (Speed Vac; Savant, Framingdale, N.Y.). The concentration of MDHP-PP was determined at 330 nm through use of a molar extinction coefficient equal to 6,200/M cm (16) .
DHPS assay procedure. The DHPS assay procedure was adapted from the methods described by Iwai and Okinaka (8) . The principal advantage of the adapted procedure is its enhanced sensitivity for DHPS activity.
The assay solution contained 100 mM Tris hydrochloride (pH 8.5), 5 mM NaF, 10 mM magnesium chloride, 2 mM ,B-mercaptoethanol, and 50 ,M [14C]pAB (specific activity, 56.6 ,uCi/,uM; Amersham Corp., Arlington Heights, Ill.) and a final concentration of MDHP-PP of 100 ,uM. The reaction was initiated by the addition of a cell extract (0.30 to 0.50 ,ug) from either Escherichia coli or P. carinii to the assay solution at room temperature. The reaction at time zero was represented by a portion that was immediately removed from the solution after the addition of the appropriate cell extract. The incubation of the remaining solution was allowed to proceed for 1 h, and the reaction was terminated by placing samples from both time zero and 1 h of incubation samples in a boiling water bath for 2 min. The samples were clarified by centrifugation at 20,000 x g for 30 min and then passed through a 0.45-,um-pore-size filter (HA; Millipore Corp.). DHPS was measured by two methods. Paper chromatography of the samples was performed by the method of Shiota et al. (16) and the HPLC method described below. Specific activities are presented as means ± standard deviations. DHPS activity was observed to be stable, changing less than 5% when it was kept at room temperature for 12 h or stored at -33°C for 1 month.
HPLC assay of DHPS. An HPLC instrument (6000; Waters Associates, Inc., Milford, Mass.) equipped with a solvent delivery system (model 6000A; Waters Associates) and a sample injector (model U6K Waters Associates) was used in the analysis of the DHPS incubation solutions. A single p.C18 column was first equilibrated with 50 mM ammonium phosphate buffer (pH 5.8). Sample volumes of 10 ,ul were injected onto the column by using a microliter syringe (801; The Hamilton Co., Reno, Nev.). The assay solution was first eluted with the ammonium phosphate buffer (pH 5.8), then with 10% methanol, and finally with 50% methanol. Samples (3 ml) from the elution profile were collected during the three-part elution and monitored by measuring the A254. A 0.2-ml portion from each sample was added to 5 ml of Aquasol, and the samples were counted in a scintillation counter (Rackbeta; LKB, Uppsala, Sweden).
Inhibition and Km studies. Kms were determined by measuring the activity of DHPS at substrate concentrations of 0, 20, 50, and 100 p.M. The 50% inhibitory concentrations (IC50s) and K,s were determined by using data for which the drugs were present in the substrate at concentrations of 0, 200, 400, and 500 ,uM, except for dapsone, which was present at concentrations of 0, 200, 300, and 500 ,uM. Plots of the log values of DHPS activity versus drug concentration were made to determine IC50s. Dixon plots were constructed as described previously (14) . All lines were drawn by linear regression analysis.
Chemicals and drugs. The following chemicals and drugs were obtained from Sigma Chemical Co. (St. Louis, Mo.): cortisone acetate, Norit-A, Dowex-50, phosphate-buffered saline buffer, 2-amino-4-hydroxy-6-hydroxymethylpterin, pyrophosphoric acid, dapsone, sulfadiazine, sulfaquinoxaline, and sulfamethoxazole. Sulfadoxine was received as a gift from Hoffmann-La Roche Inc. (Nutley, N.J.).
RESULTS
Because the enzymatic reaction was terminated in a boiling water bath, we examined the stability of our substrates and products under these conditions. When 0.5 M solutions of pAB, MDHP-PP, and DHP were boiled for 2 min, corresponding HPLC peak areas (2-,ul injections) were changed by less than 10%. Figure 1 illustrates the HPLC elution profiles from incubation mixtures containing E. coli and P. carinii. For both organisms, [14C]pAB repeatedly eluted at 5 min with 50 mM ammonium phosphate, whereas the product (pteroic acid) eluted repeatedly in 50% methanol at 28 min (Fig. 1) . Standard samples of pAB and pteroic acid eluted in a similar manner. By using HPLC to isolate the product and measure DHPS activity, the E. coli homogenate was found to contain 451 ± 46.5 (n = 4) ,uU/mg (a unit of DHPS activity is defined as 1 ,umol of DHP synthesized per h). This is similar to the specific activity determined by the standard assay (320 + 30 [n = 3] pLU/mg). In contrast, P. carinii homogenates had too little enzyme activity to be measured by the paper chromatography method. By the HPLC method, by which we were able to detect as little as 1 ,uU of activity, P. carinii homogenates were found to have 13.50 + 3.92 (n = 4) ,uU/mg. On the other hand, uninfected lung homogenates had no detectable activity (<0.002 ,uU/mg).
Having designed this repeatable and quick assay procedure, we then determined the Kms for both substrates and the effects of five sulfa drugs on P. carinii DHPS activity. The Kms for pAB and MDHP-PP were 71 and 81 ,uM, respectively. Table 1 lists the calculated IC50s and Kis of these sulfones and sulfonamides. IC50s and Kis were calculated by extrapolation from the graph. In all cases r2 > 0.92. As defined in Table 1 , the drug which most effectively inhibited this DHPS activity was dapsone. IC50s of greater than 500 ,uM were observed with sulfadoxine (42% inhibition at 500 ,uM) and sulfadiazine (1o inhibition at 500 ,uM).
DISCUSSION
In this study we demonstrated that P. carinii contains DHPS activity. Initially, we attempted to measure P. carinii DHPS activity by previously published assays (8) (9) . In addition, this value was similar to the K, for dapsone in E. coli, 5.9 ,uM (12, 15) . These data suggest that the Ki may be a more useful indicator than IC50. The effects of various sulfa drugs on the P. carinii DHPS were quite different than those on the E. coli DHPS. For example, the Ki for sulfamethoxazole in E. coli is 0.13 ,uM (12, 15) , whereas in P. carinii the K, is >400-fold greater (59 ,uM). Furthermore, in E. coli sulfadiazine (Ki = 2.5 ,uM) (12, 15 ) is a more effective inhibitor of DHPS than is dapsone, whereas in P. carinii the opposite is true. These differences may reflect fundamental differences in the enzyme-active site structures between the two species.
In summary, the data presented here indicate that various sulfonamides and sulfones have inhibitory effects on P. carinii DHPS. Further studies of inhibitors of P. carinii DHPS may uncover further leads for the development of new therapeutic regimens for P. carinii pneumonia.
